Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016 | CMAC

Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016

Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(3):260-264

​ Gomon Yu.M., Kolbin A.S.
pharmacoeconomics Russian essential drug list hard endpoints surrogate endpoints resistance
Section
Pharmacoepidemiology and Pharmacoeconomics
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(3):260-264

Objective.

To estimate proportion of hard and surrogate endpoints used as effectiveness criteria in pharmacoeconomic studies of antimicrobial drugs.

Materials and Methods.

The pharmacoeconomic studies of 30 antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014-2016 were reviewed.

Results.

A total of 47 effectiveness criteria were analyzed, of them 40.4% were hard endpoints. Two studies of antifungal drugs used the hard endpoints only. The hard endpoints were used in 58.8% of studies involving antibacterial drugs. The lowest percentage of hard endpoints was observed in studies of antiviral agents (26%).

Conclusions.

Overall, the hard endpoints comprised only 42.5% of effectiveness criteria used in pharmacoeconomic studies of antimicrobial agents, with antiviral agent studies having the lowest percentage. Antifungal therapy studies stood out due to exclusive use of hard endpoints. More than a half of effectiveness criteria used in antibacterial drug studies was the hard endpoints. Adverse events were used as the surrogate endpoints. Treatment-emergent resistance risk is an important outcome that can be used to guide decision-making process when listing pharmaceutical agents.

Yulia M. Gomon

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia

Alexey S. Kolbin

Pavlov First Saint-Petersburg State Medical University, Saint-Petersburg, Russia
Saint-Petersburg State University, Saint-Petersburg, Russia

  • 1. Marston H.D., Dixon D.M., Knisely J.M., et al. Antimicrobial Resistance. JAMA. 2016;316(11):1193-1204.
  • 2. The Federal law “On circulation of medicines”, from 12.04.2010 N 61-ФЗ. Available from: www.consultant.ru/document/cons_doc_LAW_99350/. Russian.
  • 3. Russian Federation Government Resolution of 28 August 2014 No. 871 “On Approval of the Rules for Compiling Lists of Medicines for Medical Use and the Minimum Range of Medicines Necessary for Medical Aid”. Available from: www.consultant.ru/document/cons_doc_LAW_167999/. Russian.
  • 4. Nimmo W.S., Tucker G.T., editors. Clinical Measurement in Drug Evaluation. N.Y.: J. Wiley; 1995.
  • 5. High level pharmaceutical forum 2005-2008. Conclusions and recommendations. Available from: bookshop.europa.eu/en/high-levelpharmaceutical-forum-2005-2008-pbND3008692/.
  • 6. Kleijnen S., George E., Goulden S., et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value Health. 2012;15(6):954-960.
  • 7. Luepke K.H., Suda K.J., Boucher H., et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacother. 2017;37(1):71-84.
  • 8. Institute of Medicine (IOM). Antibiotic resistance: implications for global health and novel intervention strategies: workshop summary. Washington, DC: The National Academies Press; 2010.
  • 9. Kozlov R.S. Resistance to antimicrobial drugs as a real threat to national security. Russkij medicinskij zhurnal. 2014;4:321-323. Russian.
  • 10. Schwaber M., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913-920.
  • 11. Macgowan A. BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother. 2008;62(Suppl. 2):ii105-114.
  • 12. Vorobiev P.A., Luneva A.V. Evaluation of clinical and economic effectiveness of entecavir in comparison with pegylated interferon, lamivudine, talbivudine, tenofovir in the treatment of chronic viral hepatitis B in the Russian Federation. Problemy standartizacii v zdravoohranenii. 2013;11:68-75. Russian.
  • 13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. J Hepatol. 2012;57:167185.
  • 14. Entecavir. Prescription information. Available from: www.rlsnet.ru/tn_index_id_36579.htm. Russian.
  • 15. Pegylated interferon. Prescription information. Available from: www.rlsnet. ru/tn_index_id_23210.htm. Russian.
  • 16. Telbivudin. Prescription information. Available from: www.rlsnet.ru/tn_index_id_36939.htm. Russian.
  • 17. Lamivudin. Prescription information. Available from: www.rlsnet.ru/tn_index_id_14281.htm. Russian.
  • 18. Dekhnich A.V., Nikulin A.A., Rjabkova E.L., et al. Epidemiology of Antimicrobial Resistance of S. aureus Isolated from ICU Patients in Russia: Results of Prospective Multicenter Study. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2008;10(4):333-344. Russian.
  • 19. Dekhnich A.V., Danilov A.I. Daptomycin – the Review of Pharmacological, Clinical and Microbiological Characteristics. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2010;12(4):295-313. Russian.
  • 20. Procenko D.N., Cvetkov D.S., Omel'janovskij V.V. Analysis of the clinical and economic effectiveness of antibiotic therapy regimens for angiogenic infection in intensive care units. Annaly antimikrobnoj himioterapii. 2010;(Supplement):33-40. Russian.
  • 21. Kolbin A.S., Omel'janovskij V.V., Kurylev A.A. Evaluation of final and surrogate endpoints of drugs included in reimbursement lists in 2016. Remedium. 2017;4:42-46. Russian.
  • 22. Arepyeva M.A., Kolbin A.S., Sidorenko S.V., et al. Prognostic Model of Microbial Resistance Based on the Relationship between Antibiotic Resistance and Consumption. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(3):200-211. Russian.
  • 23. Arepyeva M. A., Kolbin A.S., Sidorenko S.V., et al. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. J Global Antimicrob Resist. 2017;8(2017):148-156.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared